来氟米特联合糖皮质激素较单用激素更有效预防IgG4相关病复发
联合治疗组复发率18.2%,单药组42.4%(P=0.032),联合治疗显著延长至复发时间(HR 0.35,95%CI 0.13-0.90,P=0.023),并减少累积激素用量,安全性相似。
要点
- 联合来氟米特较单用激素显著降低IgG4相关病复发风险(HR 0.35)。
- 联合组更多患者达到每日激素≤5mg(54.5% vs 18.2%,P=0.006)。
- 两组不良事件发生率相似,联合治疗耐受性良好。
核心结论
- 来氟米特联合糖皮质激素治疗耐受性良好,在预防IgG4相关病复发方面显著优于单用糖皮质激素。
- 来氟米特可作为IgG4相关病管理中的保激素药物。
研究设计与样本
- 12个月随机开放标签对照试验,在大型学术医疗中心进行(NCT02703194)。
- 所有患者接受糖皮质激素,起始剂量0.5-0.8mg/kg/d,并按预定方案逐渐减量。
主要发现
- 联合组复发6例(18.2%),单药组14例(42.4%),差异有统计学意义(P=0.032)。
- 联合治疗在至复发时间上显著优于单药(HR 0.35,95%CI 0.13-0.90,P=0.023)。
- 联合组至完全缓解时间显著更短(HR 1.75,95%CI 1.01-3.02,P=0.034)。
- 联合组缓解持续时间更长(7.00 vs 3.00个月,P=0.002),累积激素用量更少(5103.13 vs 5637.50mg,P=0.031)。
- 联合组54.5%患者达到每日激素剂量≤5mg,单药组为18.2%(P=0.006);两组不良事件发生率相似(P=0.325)。
关键数值与推荐
- 复发率:联合组18.2% vs 单药组42.4%(P=0.032)。
- 至复发时间HR 0.35(95%CI 0.13-0.90,P=0.023)。
- 至完全缓解时间HR 1.75(95%CI 1.01-3.02,P=0.034)。
- 缓解持续时间7.00 vs 3.00个月(P=0.002)。
- 累积激素用量5103.13 vs 5637.50mg(P=0.031)。
临床怎么用
- 对活动性IgG4相关病患者,可考虑糖皮质激素联合来氟米特(20mg/天)以降低复发风险。
- 联合方案有助于减少累积激素用量,提高达到每日激素≤5mg的患者比例。
- 治疗期间不良事件发生率与单用激素相似,需常规监测。
局限性
- 开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy and safety of leflunomide (LEF) and glucocorticoids (GCs) combination therapy compared with GCs monotherapy in preventing relapse of IgG4-related disease (IgG4-RD). METHODS: A 12-month, randomized, open-label, controlled trial was conducted at a large academic medical center (ClinicalTrials.gov: NCT02703194). Enrolled patients with active IgG4-RD were randomly allocated to the GCs + LEF (20 mg/day) combination therapy or GCs monotherapy group. All patients received GCs with a predefined taper regimen starting from a dosage of 0.5-0.8 mg/kg/d. The primary outcome was the time to relapse. The secondary outcomes included complete response, remission, GCs dosage, and serum IgG4 level. RESULTS: Sixty-six patients with active IgG4-RD were enrolled (33 patients in each group). The demographic and disease characteristics showed no statistically significant differences between groups. Additionally, the initial GCs dosages were similar (50.00 vs. 50.00 mg/day, P = 0.295). Disease relapses occurred in 6 (18.2%) and 14 (42.4%) patients in the combination therapy group and GCs monotherapy group, respectively (P = 0.032). The combination therapy was significantly superior to GCs monotherapy regarding the primary outcome, the time to relapse (HR, 0.35; 95% confidence interval [CI], 0.13-0.90; P = 0.023), as well as the secondary outcome, the time to complete response (HR, 1.75; 95% CI, 1.01-3.02; P = 0.034). A longer duration of remission was observed in the combination therapy group (7.00 vs. 3.00 months, P = 0.002) and less cumulative dosage of GCs was used (5103.13 vs. 5637.50 mg, P = 0.031). Additionally, a higher proportion of patients in the combination therapy group (54.5%) were able to reach a daily GCs dose of ≤5 mg/day compared with the GCs monotherapy group (18.2%) (P = 0.006). The incidences of adverse events were similar in the 2 groups (P = 0.325). CONCLUSION: LEF in combination with GCs therapy is well-tolerated and significantly superior to GCs monotherapy in preventing the relapse of IgG4-RD. LEF can be used as a steroid-sparing agent in the management of IgG4-RD.
引用
- Wang Y, Zhao Z, Gao D, et al. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial. Semin Arthritis Rheum. 2020. PMID: 32113839. doi:10.1016/j.semarthrit.2020.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。